BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced significant expansion of its technology platform through the recent order of 30 new Deep Transcranial Magnetic Stimulation (Deep TMS™) systems for the treatment of major depressive disorder (MDD) by a large TMS network of clinics based in the Western and Central United States. Several of the systems also include an H7 Coil, thus enabling obsessive-compulsive disorder (OCD) treatment capability.
“BrainsWay is excited to partner with this growing key network customer, a leading large TMS provider in the Western and Central U.S. We are committed to bringing relief to those suffering from treatment-resistant MDD and OCD,” said Hadar Levy, Chief Executive Officer of BrainsWay. “Each Deep TMS device that becomes available to patients helps further BrainsWay’s mission to improve health and transform lives, and we are committed to ensuring that no community is deprived of access to our unique therapeutic solution.”
The large TMS network that placed this order opened its first Deep TMS center in the mid-2000s in the Southwestern U.S. and has now grown to nearly 20 clinics across 6 states in the western and central U.S. These clinics offer cutting-edge technology and the newest breakthrough treatments in psychiatry to help patients find the right treatments that work for them.
